On November 11, 2026, Maven Clinic, the women's and family health company that has raised more than $425 million, announced that care through its virtual clinic is now in-network with more than 475 health plans. Maven says those plans cover about 80% of commercially insured US lives. MedCity News reports that the plans include Aetna, UnitedHealthcare and Blue Cross Blue Shield, plus many regional insurers. The rollout begins with perimenopause, menopause and hormone-care visits, which are available now. OB-GYNs, maternal-fetal medicine specialists, nurse practitioners and nutritionists will be added "in the coming months."

Why It Matters

Menopause telehealth has mostly been a cash-pay market, built on subscriptions from companies like Midi, Hers and Evernow and on the post-label-change rush for estrogen. Maven is now offering hormone-care visits on insurance at national scale, so a woman with commercial coverage can see a menopause specialist for a copay instead of a monthly fee. That puts pricing pressure on DTC subscription competitors and pushes the category further toward insurance billing. Listing "sexual" health among the conditions employees can bring through insurance also matters: low libido, painful sex and genitourinary symptoms are among the least-treated parts of menopause care. Because demand for patches is already outstripping supply ([our shortage tracker](/stories/estradiol-patch-shortage-fda-action)), more covered prescribers could also add to pressure on supply.

Before a booking, Maven checks whether a patient has access through an employer benefit or is eligible through her health plan. Patients using insurance pay only their usual copay, coinsurance or deductible, and see an estimated cost before booking. From January 2027, employers will get a communications toolkit to promote the in-network clinic. Employees will then be able to use their own insurance for conditions such as PCOS/PMOS, endometriosis, and "hormonal, sexual, and metabolic health," even if their employer doesn't buy a Maven program.

This changes how Maven reaches patients. MedCity News notes that until now people could use Maven in three ways: through an employer-sponsored benefit (with clients such as Microsoft and AT&T), through consumer subscriptions for GLP-1 and hormone care, or by paying cash for the virtual clinic. Maven's release cites figures showing that 81% of women with menopause symptoms have never received hormone therapy and that one in five delay or avoid treatment because of cost. Chief medical officer Dr. Neel Shah previously told MedCity that companies start as self-pay to prove demand, but coverage is what creates "parity, equity and access." Founder and CEO Kate Ryder said that "healthcare doesn't happen in neat categories." The company has raised more than $425 million from investors including General Catalyst, Sequoia and Dragoneer.

Sources

Update — 2026-11-12

Initial entry — story first created.